<?xml version="1.0" encoding="UTF-8"?>
<div class="fig" id="PMC7064180/figure_2" xmlns="http://www.w3.org/1999/xhtml">
 <caption> SVR12 rates after treatment with G/P according to mITT. Abbreviations: SVR, sustained virologic response; G/P, glecaprevir/pibrentasvir; mITT, modified intention-to-treat; SS, standard setting; DOT, directly observed therapy; LTFU, lost to follow-up; HCV, hepatitis C virus; GT, genotype. A—All patients (n = 141/145). a including one patient who died 16 weeks after end of therapy for reasons not related to treatment after showing a negative HCV-RNA PCR result three weeks after end of therapy. B—Patients with advanced fibrosis (n = 21/21). Advanced fibrosis was defined as F3-F4: ≥9.5 kPa according to transient elastography. C—Patients with HCV GT3 infection (n = 54/56). </caption>
 <div class="graphic"/>
 <p class="label">Fig 2</p>
</div>
